封面
市场调查报告书
商品编码
1728102

临床前 CRO 市场 - 全球产业规模、份额、趋势、机会和预测(按服务、按模型类型、按最终用途行业、按地区和竞争细分,2020-2030 年预测)

Preclinical CRO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Service, By Model Type, By End-Use Industry, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球临床前 CRO 市场价值为 62.4 亿美元,预计到 2030 年将达到 101.5 亿美元,预测期内复合年增长率为 8.45%。该市场透过提供支援製药、生物技术和医疗器材公司临床前研究活动的基本服务,在药物开发生态系统中发挥着至关重要的作用。临床前 CRO 提供一系列服务,包括生物分析、毒理学、安全药理学和化合物管理,帮助客户满足监管要求,同时提高效率和成本效益。随着公司寻求简化营运并专注于核心竞争力,市场正受益于早期研究外包的增加。药物研发力度的加大、研究模型的技术进步以及对专业科学知识的需求进一步推动了各地区市场的成长。

市场概览
预测期 2026-2030
2024年市场规模 62.4亿美元
2030年市场规模 101.5亿美元
2025-2030 年复合年增长率 8.45%
成长最快的领域 患者来源的类器官(PDO)模型
最大的市场 北美洲

关键市场驱动因素

外包趋势日益增强推动市场成长

主要市场挑战

法规遵从和品质保证

主要市场趋势

虚拟审判数量的增加

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球临床前CRO市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按服务(生物分析和 DMPK 研究、毒理学测试、化合物管理、化学、安全药理学、其他)
    • 依模型类型(患者来源的类器官 (PDO) 模型、患者来源的异种移植模型)
    • 依最终用途产业(生物製药公司、政府和学术机构、医疗器材公司)
    • 按公司分类(2024)
    • 按地区
  • 市场地图

第六章:北美临床前CRO市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章:欧洲临床前CRO市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章:亚太临床前CRO市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章:南美临床前CRO市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲临床前 CRO 市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章: 大环境分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章:竞争格局

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Wuxi AppTec
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD, Inc.
  • SGA SA
  • Intertek Group Plc
  • LABCORP, Inc.
  • Crown Bioscience Inc

第 16 章:策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 17068

The Global Preclinical CRO Market was valued at USD 6.24 billion in 2024 and is projected to reach USD 10.15 billion by 2030, growing at a CAGR of 8.45% during the forecast period. This market plays a crucial role in the drug development ecosystem by providing essential services that support pharmaceutical, biotechnology, and medical device companies in their preclinical research activities. Preclinical CROs offer a range of services including bioanalysis, toxicology, safety pharmacology, and compound management, helping clients meet regulatory requirements while improving efficiency and cost-effectiveness. The market is benefiting from the increased outsourcing of early-stage research, as companies seek to streamline operations and focus on core competencies. The rise in drug discovery efforts, technological advancements in research models, and demand for specialized scientific expertise are further driving market growth across regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.24 Billion
Market Size 2030USD 10.15 Billion
CAGR 2025-20308.45%
Fastest Growing SegmentPatient Derived Organoid (PDO) Model
Largest MarketNorth America

Key Market Drivers

Increasing Outsourcing Trends Drives the Market Growth

A major growth driver for the Global Preclinical CRO Market is the increasing trend of outsourcing among pharmaceutical and biotechnology companies. By outsourcing preclinical R&D activities to specialized CROs, companies are able to significantly reduce costs associated with facility maintenance, personnel, and equipment. CROs offer advanced infrastructure and expert staff, allowing sponsors to accelerate timelines while ensuring regulatory compliance. This model also provides scalability, enabling companies to adapt to changing project demands without major internal investments. Moreover, CROs grant access to cutting-edge technologies and methodologies, helping clients improve research outcomes while focusing internal resources on clinical trials, regulatory strategies, and commercialization. As the demand for efficient and flexible research solutions continues to rise, outsourcing remains a preferred strategy, bolstering the growth of the preclinical CRO sector globally.

Key Market Challenges

Regulatory Compliance and Quality Assurance

The Global Preclinical CRO Market faces considerable challenges due to complex regulatory requirements and the need for strict quality assurance. Regulatory bodies such as the FDA and EMA impose rigorous standards that CROs must meet to ensure that studies are conducted ethically, accurately, and in compliance with international guidelines. Navigating diverse and evolving regulations across multiple geographies adds complexity, particularly for CROs working with global clients. Maintaining compliance requires ongoing investment in specialized personnel, documentation systems, quality audits, and training, which can strain operational resources. Delays or errors in regulatory adherence may lead to costly project setbacks or non-approval of drug candidates in later stages, underscoring the critical need for continuous regulatory vigilance and operational excellence in the CRO landscape.

Key Market Trends

Increase in the Number of Virtual Trials

A significant trend transforming the Global Preclinical CRO Market is the growing adoption of virtual or decentralized clinical trials, which leverage digital tools to collect patient data remotely. Although primarily impacting clinical phases, this trend is influencing preclinical CROs to expand their technological capabilities and align with integrated drug development models. CROs are now incorporating wearable devices, mobile apps, and telehealth platforms to facilitate remote monitoring and data collection, enabling smoother transitions from preclinical to clinical stages. These digital advancements enhance patient recruitment, diversify participation, and improve data accuracy. As a result, CROs are partnering with tech providers and investing in secure data infrastructure to support virtual research models, thereby optimizing trial efficiency and reducing dependency on traditional site-based models.

Key Market Players

  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Wuxi AppTec
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD, Inc.
  • SGA SA
  • Intertek Group Plc
  • LABCORP Inc.
  • Crown Bioscience Inc

Report Scope:

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical CRO Market, By Service:

  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Compound Management
  • Chemistry
  • Safety Pharmacology
  • Others

Preclinical CRO Market, By Model Type:

  • Patient Derived Organoid (PDO) Model
  • Patient Derived Xenograft Model

Preclinical CRO Market, By End User Industry:

  • Biopharmaceutical Companies
  • Government and Academic Institutes
  • Medical Device Companies

Preclinical CRO Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

Global Preclinical CRO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical CRO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Bioanalysis and DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)
    • 5.2.2. By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)
    • 5.2.3. By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Preclinical CRO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service
    • 6.2.2. By Model Type
    • 6.2.3. By End-Use Industry
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preclinical CRO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Model Type
        • 6.3.1.2.3. By End-Use Industry
    • 6.3.2. Mexico Preclinical CRO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Model Type
        • 6.3.2.2.3. By End-Use Industry
    • 6.3.3. Canada Preclinical CRO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Model Type
        • 6.3.3.2.3. By End-Use Industry

7. Europe Preclinical CRO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service
    • 7.2.2. By Model Type
    • 7.2.3. By End-Use Industry
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Preclinical CRO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Model Type
        • 7.3.1.2.3. By End-Use Industry
    • 7.3.2. Germany Preclinical CRO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Model Type
        • 7.3.2.2.3. By End-Use Industry
    • 7.3.3. United Kingdom Preclinical CRO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Model Type
        • 7.3.3.2.3. By End-Use Industry
    • 7.3.4. Italy Preclinical CRO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Model Type
        • 7.3.4.2.3. By End-Use Industry
    • 7.3.5. Spain Preclinical CRO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Model Type
        • 7.3.5.2.3. By End-Use Industry

8. Asia-Pacific Preclinical CRO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service
    • 8.2.2. By Model Type
    • 8.2.3. By End-Use Industry
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Preclinical CRO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Model Type
        • 8.3.1.2.3. By End-Use Industry
    • 8.3.2. India Preclinical CRO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Model Type
        • 8.3.2.2.3. By End-Use Industry
    • 8.3.3. South Korea Preclinical CRO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Model Type
        • 8.3.3.2.3. By End-Use Industry
    • 8.3.4. Japan Preclinical CRO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Model Type
        • 8.3.4.2.3. By End-Use Industry
    • 8.3.5. Australia Preclinical CRO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Model Type
        • 8.3.5.2.3. By End-Use Industry

9. South America Preclinical CRO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service
    • 9.2.2. By Model Type
    • 9.2.3. By End-Use Industry
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Preclinical CRO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Model Type
        • 9.3.1.2.3. By End-Use Industry
    • 9.3.2. Argentina Preclinical CRO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Model Type
        • 9.3.2.2.3. By End-Use Industry
    • 9.3.3. Colombia Preclinical CRO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Model Type
        • 9.3.3.2.3. By End-Use Industry

10. Middle East and Africa Preclinical CRO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service
    • 10.2.2. By Model Type
    • 10.2.3. By End-Use Industry
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Preclinical CRO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Model Type
        • 10.3.1.2.3. By End-Use Industry
    • 10.3.2. Saudi Arabia Preclinical CRO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Model Type
        • 10.3.2.2.3. By End-Use Industry
    • 10.3.3. UAE Preclinical CRO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Model Type
        • 10.3.3.2.3. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Eurofins Scientific SE
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. PRA Health Sciences, Inc.
  • 15.3. Wuxi AppTec
  • 15.4. Medpace, Inc.
  • 15.5. Charles River Laboratories International, Inc.
  • 15.6. PPD, Inc.
  • 15.7. SGA SA
  • 15.8. Intertek Group Plc
  • 15.9. LABCORP, Inc.
  • 15.10. Crown Bioscience Inc

16. Strategic Recommendations

17. About Us & Disclaimer